Although markers associated with the underlying neuropathology in AD, namely CSF Aβ and CSF tau, have remained the top candidates for AD diagnostics, these markers have also been found to be altered in other disorders such as dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and vascular dementia (VAD). This evidence concerns the gene MAPT and Alzheimer disease.